MADRIGAL PHARMACEUTICALS, INC. 4

Director Jacqualyn A. Fouse received 454 RSUs and an option to purchase 766 shares of Madrigal Pharmaceuticals, Inc. common stock as equity compensation on June 17, 2026.

On June 17, 2026, Jacqualyn A. Fouse, a director of Madrigal Pharmaceuticals, Inc., received an equity compensation package consisting of 454 shares of common stock in the form of restricted stock units and a stock option grant covering 766 shares of common stock at an exercise price of $499.86 per share, both vesting in full on the earlier of June 17, 2027 or the date of the issuer’s 2027 annual stockholders’ meeting, subject to continued service. These awards increased her direct beneficial ownership to 1,551 shares of common stock and 766 stock options, with no open-market purchases or sales reported.

Filing Facts

CIK

1157601

Ticker

MDGL

Form

4

Source Type

sec

Accession

0001628280-26-044325

Alert Tier

5